| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 3 |
| 1 | CAPECITABINE | 3 |
| 2 | ADALIMUMAB | 2 |
| 3 | ALDESLEUKIN | 2 |
| 4 | CEMIPLIMAB-RWLC | 2 |
| 5 | CYCLOPHOSPHAMIDE | 2 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 2 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 2 |
| 8 | ERGOCALCIFEROL | 2 |
| 9 | FLUDARABINE PHOSPHATE | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LIFILEUCEL | 2 | 0.0070 |
| 1 | ALDESLEUKIN | 2 | 0.0016 |
| 2 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 3 | IMIQUIMOD | 1 | 0.0004 |
| 4 | INFLIXIMAB-DYYB | 1 | 0.0003 |
| 5 | TREMELIMUMAB | 1 | 0.0002 |
| 6 | TURMERIC | 1 | 0.0002 |
| 7 | BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY | 1 | 0.0002 |
| 8 | MAGNESIUM CITRATE ORAL SOLUTION | 1 | 0.0002 |
| 9 | MAGNESIUM CITRATE | 1 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 1 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 4 | 0.0000 |
| 4 | Estrogen Receptor Antagonist [EPC] | 1 | 0.0000 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 1 | 0.0000 |
| 6 | Peroxisome Proliferator Receptor alpha Agonist [EPC] | 1 | 0.0000 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 4 | 0.0000 |
| 9 | HER2/neu Receptor Antagonist [EPC] | 1 | 0.0000 |